Testing a new treatment for children with aggressive brain tumors
Phase 0/1 trial of ONC206 - a novel imipridone for children with diffuse midline gliomas and recurrent malignant brain tumors
['FUNDING_R01'] · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · NIH-10917106
This study is testing a new oral medication called ONC206 to see how safe and effective it is for children with malignant brain tumors, especially those with diffuse midline gliomas, by helping the body get rid of damaged brain cells.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (nih funded) |
| Locations | 1 site (SAN FRANCISCO, UNITED STATES) |
| Trial ID | NIH-10917106 on ClinicalTrials.gov |
What this research studies
This research investigates the safety and early effectiveness of a new oral medication called ONC206 for children suffering from malignant brain tumors, particularly diffuse midline gliomas. The study aims to understand how ONC206 works by activating a specific protein that helps eliminate damaged cells in the brain. Participants will receive this treatment and be monitored for any side effects and how well the medication works. The trial will include various groups of pediatric patients, including those newly diagnosed and those whose tumors have returned.
Who could benefit from this research
Good fit: Ideal candidates for this research are pediatric patients diagnosed with diffuse midline gliomas or recurrent malignant brain tumors.
Not a fit: Patients with non-malignant brain tumors or those who do not meet the specific criteria for this trial may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option that improves survival rates for children with aggressive brain tumors.
How similar studies have performed: Other research has shown promising results with similar approaches targeting mitochondrial pathways in cancer treatment, suggesting potential for success in this novel application.
Where this research is happening
SAN FRANCISCO, UNITED STATES
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO — SAN FRANCISCO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MUELLER, SABINE — UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- Study coordinator: MUELLER, SABINE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.